Fletikumab

Last updated
Fletikumab
Monoclonal antibody
Type ?
Target IL20
Clinical data
Other namesNNC0109-0012
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C6494H10000N1728O2050S44
Molar mass 146492.12 g·mol−1

Fletikumab (NNC0109-0012) (INN [1] ) is a monoclonal antibody designed for the treatment of rheumatoid arthritis. [2]

This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.

Related Research Articles

An international nonproprietary name (INN) is an official generic and non-proprietary name given to a pharmaceutical drug or an active ingredient. INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since 1953.

Drug nomenclature

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are the International Nonproprietary Names (INNs); and trade names, which are brand names. Generic names for drugs are nowadays constructed out of affixes and stems that classify the drugs into different categories and also separate drugs within categories. A marketed drug might also have a company code or compound code.

Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.

Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator.

Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC

Lulizumab pegol is a monoclonal antibody designed for the treatment of autoimmune diseases.

Lifastuzumab vedotin is a monoclonal antibody designed for the treatment of cancer.

Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies.

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.

Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies.

Seribantumab is a monoclonal antibody designed for the treatment of cancer.

Lumretuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Plozalizumab is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.

Vobarilizumab is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.

Brazikumab is a human monoclonal antibody designed for the treatment of Crohn's disease.

Bleselumab is a human monoclonal antibody designed for the prevention of organ transplant rejection.

Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

Pamrevlumab is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer.

References

  1. ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association .


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.